Physician profile
Robert Balandis
NPI 1063520617
$932.11
in general payments reported to CMS, 2019-2025
17 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $196 · 2021: $94.56 · 2022: $102 · 2023: $38.38 · 2024: $64.70 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $137.02 | 2025 | Blincyto |
| Shire North American Group INC | $132.22 | 2019 | |
| Abbott Laboratories | $107.98 | 2020 | |
| Janssen Biotech, INC. | $104.00 | 2021-2025 | Tecvayli, Talvey, Darzalex |
| Portola Pharmaceuticals, LLC | $88.48 | 2020 | |
| Alexion Pharmaceuticals, INC. | $66.05 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $53.40 | 2025 | |
| Seqirus USA INC | $36.62 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Kerecis Limited | $32.18 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Tersera Therapeutics LLC | $28.46 | 2024 | Zoladex |
| Sobi, INC | $27.89 | 2021 | |
| Csl Behring | $26.72 | 2025 | Kcentra |
| Heron Therapeutics, INC. | $23.26 | 2022 | |
| Purdue Pharma L.P. | $20.23 | 2025 | Nalmefene Hydrochloride |
| Genentech, INC. | $20.12 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.74 | 2021 | |
| Abbvie INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Balandis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.